working
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We have begun to strategically partner with other pharmaceutical companies through licensing agreements.
IPIX
I Agree: HAVE BEGUN
FROM 10K "We currently own all development and marketing rights to our investigational products, other than the rights granted to Alfasigma for the development, manufacturing and commercialization of locally-administered Brilacidin for UP/UPS. We have begun to strategically partner with other pharmaceutical companies through licensing agreements."
strange? https://www.google.com/search?q=Ehrlich&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjopqmI6_zkAhWE2eAKHXxnBZ4Q_AUIEigB&biw=1366&bih=625
They are also cousins, brothers, Leo's nephews?
"the burden of proof always lies with the person who lays charges."
The burden of proof is usually on the person who brings a claim in a dispute. It is often associated with the Latin maxim semper necessitas probandi incumbit ei qui agit, a translation of which in this context is: "the necessity of proof always lies with the person who lays charges."
It is basic, elementary, first of law
I think in this world, even in the stock market,
"Not everything is valid"
usual in all presentations of OTC companies
nothing new,
“We are very selective in deciding which companies to work with,” said Chris Ehrlich, Managing Director and Global Head of Biopharma at Locust Walk. “We look forward to working with Innovation Pharmaceuticals to help them determine the market potential and the best path forward to create value.”
IPIX
BEVERLY, MA – September 30, 2019 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the Company has engaged Locust Walk, a leading global life sciences transaction firm. Locust Walk will seek to assist the Company in maximizing the value of its assets.
FROM 10K"...Alfasigma will be solely responsible for all costs and expenses associated with developing, manufacturing and commercializing Brilacidin for UP/UPS."
IPIX
FROM 10K "...and will make additional payments of up to $24.0 million to the Company based upon the achievement of certain milestones, including a $1.0 million payment due following commencement of the first phase III clinical trial of Brilacidin for UP/UPS and an additional $1.0 million payment upon the filing of a marketing approval application with the U.S. Food and Drug Administration or the European Medicines Agency."
IPIX
Chris Ehrlich, born 2-9-70, 49 years old
Leo Ehrlich, 60 years old
Some people have written on the message board that it is your child!
yes of course, Leo was a father with 11 years ... LOL
the question is to write something negative, no matter what
"...Innovation Pharmaceuticals $IPIX To Be Scooped Up In Cash And Stock Transaction By Unnamed Nasdaq Traded Company, Official PR Coming Early Next Week..."
ipix
hitting the hard ASK
IPIX
one more step...
IPIX
BEVERLY, MA – September 30, 2019 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the Company has engaged Locust Walk, a leading global life sciences transaction firm. Locust Walk will seek to assist the Company in maximizing the value of its assets.
“It is an exciting time at Innovation,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Our pipeline is innovative, mature, and diversified, targeting therapeutic areas encompassing significant market opportunities—namely, in Inflammatory Bowel Disease, Dermatology, Cancer, and Infectious Disease. With our first global licensing agreement executed in July with Italy’s Alfasigma in Ulcerative Proctitis/Ulcerative Proctosigmoiditis, we continue to diligently work toward completing other transactions that would unlock additional shareholder value. As such, we are thrilled to engage Locust Walk—with their proven track record and global footprint.”
“We are very selective in deciding which companies to work with,” said Chris Ehrlich, Managing Director and Global Head of Biopharma at Locust Walk. “We look forward to working with Innovation Pharmaceuticals to help them determine the market potential and the best path forward to create value”
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Locust Walk
Locust Walk is a leading life sciences transaction advisory firm focused on biopharmaceutical and medical technology companies. Its team of experienced professionals fuels the growth of promising companies at every stage by connecting the right products, the right partners and the most attractive sources of capital—driving innovation for growth and transformative results. Locust Walk was founded in 2009 and currently has offices in Boston; San Francisco; London; and Tokyo. For further information, including recent transactions and engagements, please visit: http://www.locustwalk.com.
"...Innovation Pharmaceuticals $IPIX To Be Scooped Up In Cash And Stock Transaction By Unnamed Nasdaq Traded Company, Official PR Coming Early Next Week..."
regarding a publication that says:
"...but it is a smaller mid-size European pharma with some international presence".
I agree that it is a medium-sized pharma,
but some observations:
-6 locations in ITALY
-Spain
-3 in the USA
-France
-2 in China
-Czech Republic
-Slovakia
-Tunisia
-Mexico
-Poland
-Portugal
-Romania
-Belgium
-Russia
-India
-2 in Holland
-Switzerland
European Pharma ?, of course,
but that includes many countries,
I would say more specifically Italian pharma,
presence in many countries and also continents (Europe, Asia, North America, Central America, Africa ...)
https://www.alfasigma.com/en/contacts/alfasigma-worldwide
Exactly, I have an account with a broker that allows foreign accounts,
I make a bank transfer (it takes about 48 hours)
and everything ready,
ADR? no
ADRs are for foreign companies that are listed on US markets
sales "pacted"?
NT is usual in otc
has no impact on PPS
IMO
yes, 103.352
Are you sure of this?
"why bother? Leo is going to do whatever he wants. I've already wasted my money, I'm not going to waste my time"
at last!
I see you more optimistic, in regards to the price
welcome to the "other side"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151117502
someone writes "four" topics that were discussed ...
the rest believe it as if it were the "bible"
they draw their conclusions, as if it were all true,
and ... word "divine"
it's funny funny
nobody attends the meeting,
nobody knows what was said at the meeting,
but as always, everyone speculates on the issues that were discussed
and what is worse,
they draw conclusions from something that perhaps was not even spoken
what happened? 14-16-18
anyone's big toe?
0.14 X 0.1440
IPIX
BID increasing,
for the first time in weeks
IPIX
IPIX +5.7%
IPIX 0.14$
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151175216
Tuesday, 09/17/19 07:06:12 AM
my post yesterday first thing
Why underlined and the link?
it's clear:
they could have put the BDD website link,
All the information is there,
they wanted to relate the name Novartis with BDD and ...
we are on our way to 0.20, in principle
And why not to the Bdd website?
to a PR novartis-Bdd?
because in yesterday's news there is a link to the Novartis BDD Pharma agreement?
Wouldn't a link to the BDD Pharma website be more logical?
https://www.otcmarkets.com/stock/IPIX/news/Innovation-Pharmaceuticals-Announces-Successful-Formulation-of-Oral-Brilacidin-Tablets-Upcoming-Clinical-Trial-to-Target?id=240470
Here is all the information about OralogiK
https://www.bddpharma.com/
It makes no sense to address a Bdd-Novartis news ...
or if?
IPIX tic, toc, tic, toc